Comparisons of Δ9-Tetrahydrocannabinol and Anandamide on a Battery of Cognition-Related Behavior in Nonhuman Primates
- 1 April 2016
- journal article
- research article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 357 (1) , 125-133
Abstract
The primary psychoactive ingredient of marijuana, Δ9-tetrahydrocannabinol (Δ9-THC), has medicinal value but also produces unwanted deleterious effects on cognitive function, promoting the search for improved cannabinergic therapeutics. The present studies used a battery of touchscreen procedures in squirrel monkeys to compare the effects of different types of cannabinergic drugs on several measures of performance including learning (repeated acquisition), cognitive flexibility (discrimination reversal), short-term memory (delayed matching-to-sample), attention (psychomotor vigilance), and motivation (progressive ratio). Drugs studied included the cannabinoid agonist Δ9-THC, fatty acid amide hydrolase (FAAH) inhibitor cyclohexylcarbamic acid 3-carbamoylbiphenyl-3-yl ester (URB597), and endocannabinoid anandamide and its stable synthetic analog methanandamide [(R)-(+)-arachidonyl-1′-hydroxy-2′-propylamide]. The effects of Δ9-THC and anandamide after treatment with the cannabinoid receptor type 1 inverse agonist/antagonist rimonabant [5-(4-chlorophenyl)-1-(2,4-dichloro-phenyl)-4-methyl-N-(piperidin-1-yl)-1Hpyrazole-3-carboxamide] and the FAAH inhibitor URB597, respectively, also were examined. The results showed the following: 1) Δ9-THC produced dose-related impairments of discrimination-based cognitive behavior with potency that varied across tasks (discriminative capability < learning < flexibility < short-term memory); 2) anandamide alone and URB597 alone were without effect on all endpoints; 3) anandamide following URB597 pretreatment and methanandamide had negligible effects on discriminative capability, learning, and reversal, but following large doses affected delayed matching-to-sample performance in some subjects; 4) all drugs, except anandamide and URB597, disrupted attention; and 5) progressive ratio breakpoints were generally unaffected by all drugs tested, suggesting little to no effect on motivation. Taken together, these data indicate that metabolically stable forms of anandamide may have lesser adverse effects on cognitive functions than Δ9-THC, possibly offering a therapeutic advantage in clinical settings.Keywords
This publication has 45 references indexed in Scilit:
- Critical appraisal of the potential use of cannabinoids in cancer managementCancer Management and Research, 2013
- Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokersMolecular Psychiatry, 2011
- The fatty acid amide hydrolase inhibitor URB 597: interactions with anandamide in rhesus monkeysBritish Journal of Pharmacology, 2011
- ON THE DEVELOPMENT AND MECHANICS OF DELAYED MATCHING-TO-SAMPLE PERFORMANCEJournal of the Experimental Analysis of Behavior, 2011
- An Evidence-Based Review of Acute and Long-Term Effects of Cannabis Use on Executive Cognitive FunctionsJournal of Addiction Medicine, 2011
- Effects of endocannabinoid system modulation on cognitive and emotional behaviorFrontiers in Behavioral Neuroscience, 2011
- Age-related cognitive deficits in rhesus monkeys mirror human deficits on an automated test batteryNeurobiology of Aging, 2010
- Effects of MDMA, methamphetamine and methylphenidate on repeated acquisition and performance in ratsPharmacology Biochemistry and Behavior, 2009
- The FAAH inhibitor URB-597 interferes with cisplatin- and nicotine-induced vomiting in the Suncus murinus (house musk shrew)Physiology & Behavior, 2009
- Prolonged Recovery Rate of CB1 Receptor Adaptation after Cessation of Long-Term Cannabinoid AdministrationMolecular Pharmacology, 2006